Nonivamide

Summary

Nonivamide (CHEMBL75124) is a phase-3 clinical-stage small-molecule lachrymator; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 2
• Chemistry: 293.4 Da · C17H27NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL75124
Name	Nonivamide
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	2998
ChEBI	CHEBI:46936
Molecular formula	C17H27NO3
Molecular weight	293.4
InChIKey	RGOVYLWUIBMPGK-UHFFFAOYSA-N

SMILES: CCCCCCCCC(=O)NCC1=CC(=C(C=C1)O)OC

IUPAC name: N-[(4-hydroxy-3-methoxyphenyl)methyl]nonanamide

ChEBI definition: A capsaicinoid that is the carboxamide resulting from the formal condensation of the amino group of 4-hydroxy-3-methoxybenzylamine with the carboxy group of nonanoic acid. It is the active ingredient in many pepper sprays.

Pharmacological roles (ChEBI): lachrymator.

Also known as: AH-23491X, FEMA NO. 2787, Hansaplast, Hydroxymethoxybenzyl pelargonamide, N-vanillylnonamide, Nonivamida, Nonivamide, Nonylic acid vanillyamide, NSC-172795, Pseudocapsaicin, N-Vanillylnonanamide, SID11111961

Patent coverage: 2,244 distinct patent families (5,795 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,602 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: RecQ-like DNA helicase BLM, Ferritin light chain, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Endonuclease 4, Peripheral myelin protein 22, Vanilloid receptor, Muscarinic acetylcholine receptor M1, Cytochrome P450 2D6, Polyunsaturated fatty acid lipoxygenase ALOX15, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 3A4, Aldehyde dehydrogenase 1A1, Cytochrome P450 2C19, Transient receptor potential cation channel subfamily V member 1.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 26 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
O35433	6.65	EC50	223	nM	CHEMBL_ACT_10957764
O35433	6.26	EC50	550	nM	CHEMBL_ACT_781560
O35433	6.26	EC50	550	nM	CHEMBL_ACT_854044
O35433	6.26	EC50	550	nM	CHEMBL_ACT_93406
P0A6C1	6.15	Potency	707.9	nM	CHEMBL_ACT_4084683
O35433	5.91	Ki	1223	nM	CHEMBL_ACT_10957739
P08482	5.8	Potency	1585	nM	CHEMBL_ACT_4857752
CYP2C9	5.5	Potency	3162	nM	CHEMBL_ACT_5017072
CYP2C9	5.5	AC50	3162	nM	CHEMBL_ACT_6010757
CYP3A4	5.4	Potency	3981	nM	CHEMBL_ACT_4973652
CYP3A4	5.4	Potency	3981	nM	CHEMBL_ACT_5038913
CYP3A4	5.4	AC50	3981	nM	CHEMBL_ACT_6009731
CYP2C19	5.1	Potency	7943	nM	CHEMBL_ACT_4019363
CYP2C19	5.1	AC50	7943	nM	CHEMBL_ACT_6008762
PMP22	5.07	Potency	8492	nM	CHEMBL_ACT_4358495

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01708915	PHASE3	COMPLETED	Nonivamide/Nicoboxil Ointment in Acute Low Back Pain
NCT02300311	PHASE3	COMPLETED	Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).